Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Neoplasias Pleurales/diagnóstico , Pleuresia/diagnóstico , Leucemia de Células Plasmáticas/diagnóstico , Derrame Pleural/diagnóstico , Derrame Pleural/etiología , Derrame Pleural/patología , Neoplasias Pleurales/complicaciones , Neoplasias Pleurales/patología , Pleuresia/etiología , Pleuresia/patología , Radiografía Torácica , Leucemia de Células Plasmáticas/complicaciones , Leucemia de Células Plasmáticas/patología , Resultado Fatal , MarruecosRESUMEN
Background: Primary plasma cell leukemia (pPCL) is uncommon, aggressive and has a different biology than multiple myeloma (MM). Aim: To report the features of patients with pPCL. Material and Methods: Review of databases of the Hematology Department and the Hematology laboratory. Results: Of 178 patients with monoclonal gammopathies, five (2.8%) patients aged 33 to 64 years (three females) had a pPCL. The mean hemoglobin was 7.3 g/dL, the mean white blood cell count was 52,500/mm3, with 58% plasma cells, and the mean platelet count was 83,600/mm3. The mean bone marrow infiltration was 89%, LDH was 2,003 IU/L, serum calcium was 13 mg/dL, and creatinine 1.5 mg/dL. Two patients had bone lesions. Three were IgG, one IgA lambda and one lambda light chain. CD20 was positive in one, CD56 was negative in all and CD117 was negative in 3 cases. By conventional cytogenetic analysis, two had a complex karyotype. By Fluorescence in situ Hybridization, one was positive for TP53 and another for t (11; 14). One patient did not receive any treatment, three patients received VTD PACE and one CTD. None underwent transplant. Three patients are alive. The mean survival was 14 months. Conclusions: These patients with pPCL were younger and had a more aggressive clinical outcome than in multiple myeloma.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Leucemia de Células Plasmáticas/genética , Leucemia de Células Plasmáticas/epidemiología , Paraproteinemias/genética , Paraproteinemias/patología , Paraproteinemias/epidemiología , Recuento de Células Sanguíneas , Leucemia de Células Plasmáticas/patología , Leucemia de Células Plasmáticas/terapia , Análisis de Supervivencia , Chile/epidemiología , Calcio/sangre , Estudios Retrospectivos , Resultado del Tratamiento , Hibridación Fluorescente in Situ , Creatinina/sangre , Análisis Citogenético , Citometría de Flujo/métodosRESUMEN
Background: Plasma cell leukemia (PCL) is a rare but aggressive subtype of plasma cell dyscrasia. It is known to present with highly variable morphological features and may mimic with other lymphoid neoplasms. Multicolor flow cytometry (MFC) with availability of newer markers is highly useful in the diagnosis of the plasma cell leukemia. We present an immunophenotypic profile in ten cases of PCL along with their clinical and laboratory findings. Materials and Methods: We retrospectively studied immunophenotypic profile of 10 cases of plasma cell leukemia (out of 4615 cases of hematolymphoid neoplasms) using five parameter, three color flow cytometric analysis. We also studied their clinical presentation and other laboratory findings. Results: Common clinical features at presentation were weakness, bone pain, anemia, thrombocytopenia and osteolytic lesions. Plasma cell population was identified on strong expression of CD38 and co-expression of CD38 and CD138. CD56 was expressed in 44% cases. CD19 and CD20 were negative in all cases. Surface light chain restriction was seen in 50% cases and in remaining 50% cases revealed cytoplasmic light chain restriction. CD117 was expressed in one out of two cases studied. Conclusions: MFC immunophenotyping is highly useful to differentiate Plasma cell leukemia from other chronic lymphoproliferative disorders with plasmacytoid morphology as well as from non-neoplastic reactive PC and co-expression of CD38 and CD138 is a best combination to identify the plasma cells by MFC.
Asunto(s)
Antígenos CD/análisis , Citometría de Flujo , Humanos , Inmunofenotipificación , India , Leucemia de Células Plasmáticas/patología , Células Plasmáticas/química , Estudios RetrospectivosRESUMEN
Background: Plasma cell leukemia (PCL) is a rare but aggressive subtype of plasma cell dyscrasia. It is known to present with highly variable morphological features and may mimic with other lymphoid neoplasms. Multicolor flow cytometry (MFC) with availability of newer markers is highly useful in the diagnosis of the plasma cell leukemia. We present an immunophenotypic profile in ten cases of PCL along with their clinical and laboratory findings. Materials and Methods: We retrospectively studied immunophenotypic profile of 10 cases of plasma cell leukemia (out of 4615 cases of hematolymphoid neoplasms) using five parameter, three color flow cytometric analysis. We also studied their clinical presentation and other laboratory findings. Results: Common clinical features at presentation were weakness, bone pain, anemia, thrombocytopenia and osteolytic lesions. Plasma cell population was identified on strong expression of CD38 and co-expression of CD38 and CD138. CD56 was expressed in 44% cases. CD19 and CD20 were negative in all cases. Surface light chain restriction was seen in 50% cases and in remaining 50% cases revealed cytoplasmic light chain restriction. CD117 was expressed in one out of two cases studied. Conclusions: MFC immunophenotyping is highly useful to differentiate Plasma cell leukemia from other chronic lymphoproliferative disorders with plasmacytoid morphology as well as from non-neoplastic reactive PC and co-expression of CD38 and CD138 is a best combination to identify the plasma cells by MFC.
Asunto(s)
Antígenos CD/análisis , Citometría de Flujo , Humanos , Inmunofenotipificación , India , Leucemia de Células Plasmáticas/patología , Células Plasmáticas/química , Estudios RetrospectivosRESUMEN
We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre. Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL). Most of the PBL are extranodal in location and are mucosa-based. We reviewed the morphological features of 34 cases of PBL. Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based). We classified PBL into three morphological subtypes (immunoblastic - 25, Burkitt's - 7, plasmacytic - 2). Tumor cells expressed as leucocyte common antigen (LCA) in 60%, CD138 in 100%, EMA in 45% and light chain restriction in 86% cases. CD20 was negative in all cases. Pathologists need to be aware of PBL and its various morphological subtypes as the identification of this entity from its close differentials carries major therapeutic implications.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Adolescente , Adulto , Anciano , Antígenos CD20/análisis , Antígenos Comunes de Leucocito/análisis , Linfoma de Burkitt/patología , Niño , Femenino , Humanos , Cadenas Ligeras de Inmunoglobulina/análisis , Leucemia de Células Plasmáticas/patología , Linfoma Relacionado con SIDA/patología , Linfoma Inmunoblástico de Células Grandes/patología , Masculino , Persona de Mediana Edad , Sindecano-1/análisisRESUMEN
A rare case of plasma cell leukaemia and papillary serous cystadenacarcinoma of ovary in a 58-year-old female is reported.
Asunto(s)
Cistadenocarcinoma Papilar/patología , Femenino , Humanos , Leucemia de Células Plasmáticas/patología , Persona de Mediana Edad , Neoplasias Primarias Múltiples/patología , Neoplasias Ováricas/patologíaRESUMEN
Um caso raro de leucemia plasmocitária primária com excreçäo de cadeias leves do tipo lambda é relatado como uma discrasia plasmática, caracterizada por plasmocitose no sangue e medula óssea, escassa lesäo osteolítica e quadro clínico de insuficiência cardíaca e renal. A morfologia das células apresentava diferentes estágios de diferenciaçäo e maturaçäo. Foi identificada excreçäo de proteína de Bence-Jones tipos lambda na urina e no soro. A paciente foi tratada com quimioterapia (esquema M2) e sobreviveu por 33 meses, indicando resposta a terapêutica
Asunto(s)
Adulto , Humanos , Femenino , Cadenas lambda de Inmunoglobulina/análisis , Leucemia de Células Plasmáticas/diagnóstico , Células Plasmáticas/análisis , Riñón/fisiopatología , Leucemia de Células Plasmáticas/patología , Médula Ósea/patología , Células Plasmáticas/patologíaRESUMEN
Comunicamos en este trabajo un paciente con leucemia de células plasmáticas, cuya presentación de novo, pronóstico y evolución difieren del mieloma múltiple. Se mencionan los criterios diagnósticos y se discute esta entidad